Liquidia Corporation (LQDA)
Liquidia: Yutrepia's Attributes In Focus, But Binary Risk Shouldn't Be Ignored
Liquidia Corporation remains a Buy for risk-tolerant biotech investors, supported by strong Yutrepia launch metrics and product differentiation in PAH and PH-ILD. LQDA's Yutrepia demonstrates superior tolerability, higher achievable dosing, and rapid titration versus Tyvaso, driving robust commercial uptake and market share gains. Key binary risk centers on the imminent IP litigation outcome versus United Therapeutics; multiple scenarios could impact valuation, but commercial momentum is strong.
Take the Zacks Approach to Beat the Markets: Liquidia, Western Digital & Johnson & Johnson in Focus
Liquidia shares have surged 43.9% since an October upgrade, as Zacks highlights stock wins and portfolio results despite a volatile market.
Wall Street Analysts See a 51.15% Upside in Liquidia Corporation (LQDA): Can the Stock Really Move This High?
The consensus price target hints at a 51.2% upside potential for Liquidia Corporation (LQDA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Liquidia Corporation (LQDA) Presents at Jefferies London Healthcare Conference 2025 Transcript
Liquidia Corporation ( LQDA ) Jefferies London Healthcare Conference 2025 November 18, 2025 8:00 AM EST Company Participants Roger Jeffs - CEO & Director Michael Kaseta - COO & CFO Conference Call Participants Amy Li - Jefferies LLC, Research Division Presentation Amy Li Jefferies LLC, Research Division Hi, everyone, thanks so much for attending the Liquidia fireside chat. Day 2 of the conference, the weather in London is getting a little chilly, but it's good for staying awake.
Wall Street Analysts Think Liquidia Corporation (LQDA) Could Surge 62.34%: Read This Before Placing a Bet
The consensus price target hints at a 62.3% upside potential for Liquidia Corporation (LQDA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Liquidia Corporation (LQDA) Q3 2025 Earnings Call Transcript
Liquidia Corporation ( LQDA ) Q3 2025 Earnings Call November 3, 2025 8:30 AM EST Company Participants Jason Adair - Chief Business Officer Roger Jeffs - CEO & Director Michael Kaseta - COO & CFO Scott Moomaw - Chief Commercial Officer Rajeev Saggar - Chief Medical Officer Russell Schundler - General Counsel & Corporate Secretary Conference Call Participants Amy Li - Jefferies LLC, Research Division Cory Jubinville - LifeSci Capital, LLC, Research Division Julian Harrison - BTIG, LLC, Research Division Ryan Deschner - Raymond James & Associates, Inc., Research Division Serge Belanger - Needham & Company, LLC, Research Division Andrew Fein - H.C. Wainwright & Co, LLC, Research Division Benjamin Burnett - Wells Fargo Securities, LLC, Research Division Jason Gerberry - BofA Securities, Research Division Presentation Operator Good morning, and welcome to the Liquidia Corporation Third Quarter 2025 Financial Results and Corporate Update Conference Call.
Liquidia Corporation (LQDA) Discusses Innovations in Inhaled Treprostinil Therapies and Updates on Drug Delivery Technologies Transcript
Liquidia Corporation ( LQDA ) Discusses Innovations in Inhaled Treprostinil Therapies and Updates on Drug Delivery Technologies October 28, 2025 2:00 PM EDT Company Participants Roger Jeffs - CEO & Director Rajeev Saggar - Chief Medical Officer Jason Adair - Chief Business Officer Conference Call Participants Richard Channick Rajan Saggar Ricardo Restrepo-Jaramillo Julian Harrison - BTIG, LLC, Research Division Cory Jubinville - LifeSci Capital, LLC, Research Division Pavan Patel - BofA Securities, Research Division Amy Li - Jefferies LLC, Research Division Benjamin Burnett - Wells Fargo Securities, LLC, Research Division Ryan Deschner - CGS International Presentation Roger Jeffs CEO & Director Well, great. Thank you, everybody, for being seated.
Liquidia Technologies, Inc. (LQDA) Reports Q2 Loss, Beats Revenue Estimates
Liquidia Technologies, Inc. (LQDA) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to a loss of $0.37 per share a year ago.
What Next For Liquidia After Launch?
Liquidia shipped its first FDA-approved product, Yutrepia for pulmonary hypertension in June entering market worth several billion dollars. Market sentiment remains skeptical, pricing in limited Yutrepia success despite a large addressable market and competitor United Therapeutics' strong sales. Valuation scenarios suggest substantial upside if LQDA captures meaningful market share, but capital raises and medium-term competition could weigh on expectations.
Liquidia Corporation (LQDA) Q1 2025 Earnings Call Transcript
Liquidia Corporation (NASDAQ:LQDA ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Jason Adair - Chief Business Officer Roger Jeffs - Chief Executive Officer Michael Kaseta - Chief Operating Officer and Chief Financial Officer Rusty Schundler - General Counsel Rajeev Saggar - Chief Medical Officer Scott Moomaw - Chief Commercial Officer Conference Call Participants Julian Harrison - BTIG, LLC Kambiz Yazdi - Jefferies Group LLC Greg Harrison - Scotiabank Cory Jubinville - LifeSci Capital Serge Belanger - Needham & Company, LLC Ryan Deschner - Raymond James Financial, Inc. Operator Good morning, and welcome everyone to the Liquidia Corporation First Quarter 2025 Financial Results and Corporate Update Conference Call. My name is Ari, and I will be your conference operator today.
Liquidia Technologies, Inc. (LQDA) Reports Q1 Loss, Misses Revenue Estimates
Liquidia Technologies, Inc. (LQDA) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $0.54 per share a year ago.
Liquidia Corporation: A Strong Buy On High Likelihood Of FDA Approval This Month
Liquidia Corporation's legal victory clears the path for Yutrepia's FDA approval and market entry, targeting PAH and PH-ILD, with final approval expected by May 24, 2025. Yutrepia's competitive advantages include a patient-friendly inhaler, lower cost structure, and strong clinical profile, positioning it to capture market share from United Therapeutics' Tyvaso DPI. Liquidia is financially prepared for Yutrepia's launch, boasting $176.5 million in cash and milestone financing, ensuring a smooth commercialization without diluting shareholders.
